Bayer launches Phase III clinical study of Trasylol in elective spinal fusion surgery

December 08, 2005

Bayer Pharmaceuticals Corporation (NYSE: BAY) today announced the initiation of a Phase III clinical trial to evaluate the safety and efficacy of Trasylol® (aprotinin injection) in reducing blood loss and the need for transfusion in adult patients undergoing elective spinal fusion surgery.

Spinal fusion surgery involves 'fusing' together one or more of the small bones of the spine with bone grafts and devices. This fusion limits the motion between the vertebrae allowing surgeons to treat injuries to the spine, repair broken vertebra, correct deformities, adjust abnormal curvatures, stabilize weakness and remedy slipped or herniated disks. Approximately 300,000 spinal fusion surgeries take place each year in the United States, a figure that has doubled in the last decade (1).

Patients undergoing spinal fusion surgery are subject to a blood transfusion rate that may be six times greater than that of patients undergoing spinal surgery without fusion (2). Spine fusion surgery is also associated with more complications (such as infection, chronic pain and neural injuries) as it requires more extensive dissection and longer operative time (3).

"Blood loss can be a significant complication of spine surgery. Combined with the potential health risks associated with transfusions and the rising cost of blood products, there is a great need to reduce bleeding in this surgical setting," said Michael Neuwirth, MD, lead investigator of the study and director of the Spine Institute at Beth Israel Medical Center. "Trasylol has been proven safe and effective in reducing blood loss and transfusion requirements in coronary artery bypass surgery, and we are studying the drug to determine if it may play a similar role in spinal fusion surgery."

The multi-center, randomized, double-blind, placebo-controlled trial will assess the ability of Trasylol to reduce bleeding and the need for blood transfusions in elective spinal fusion surgery involving three to seven vertebral levels. Over 450 adult patients will be randomly assigned to receive 200 mL of intravenous Trasylol or placebo at the start of the operation, followed by 50 mL/hour of either agent until the surgery is complete. An initial IV test dose will also be administered. Close to 40 investigational centers in North America will participate in the study.

Trasylol is currently approved for use in more than 60 countries. In the United States, Trasylol is indicated for prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass (CPB) in the course of coronary artery bypass graft (CABG) surgery.

"Studies have continued to provide evidence supporting the hemostatic effects of Trasylol in orthopedic surgery," said Dr. Paul MacCarthy, Vice President of Medical Affairs at Bayer. "We are hopeful that this clinical trial will validate those findings and establish the safety and efficacy of Trasylol therapy in the setting of spinal fusion surgery."

In April 2005, Bayer had announced the initiation of a Phase III study to evaluate the safety and efficacy of Trasylol in reducing blood loss and the need for transfusion in patients undergoing elective primary total hip replacement surgery.
-end-
  1. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project, HCUPnet. Accessed on November 9, 2005. Available at: http://www.ahrq.gov/data/hcup/.
  2. Deyo RA, et al. Lumbar spinal fusion: a cohort study of complications, reoperations, and resource use in the Medicare population. Spine 1993;18:1463-1470.
  3. Ibid.


  4. GCI Group

    Related Clinical Trial Articles from Brightsurf:

    Clinical trial investigates gabapentin for alcohol use disorder
    This randomized clinical trial investigated if gabapentin, a drug often used to treat nerve pain, would be useful in the treatment of patients with alcohol use disorder (problem drinking that becomes severe) and a history of alcohol withdrawal symptoms.

    Electrical stimulation helps treat constipation in clinical trial
    Electrical stimulation benefited women with constipation in a recent clinical trial published in Alimentary Pharmacology & Therapeutics.

    Treatment of migraine pain in randomized clinical trial
    Adults experiencing a migraine of moderate or severe severity took the drug ubrogepant or placebo and reported if after two hours they were free of pain and of their most bothersome migraine-associated symptom in this randomized clinical trial.

    First entirely digital clinical trial encourages physical activity
    As little as a daily ping on your phone can boost physical activity, researchers from the Stanford University School of Medicine and their collaborators report in a new study.

    HIV vaccine nears clinical trial following new findings
    A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version of the vaccine has been shown to provide similar protection as its original version.

    Sickle cell drug showing promise in clinical trial
    An investigational drug for the treatment of sickle cell disease is showing early promise in clinical trials for impacting biomarkers of the disease in patients, reported UConn School of Medicine researchers.

    Meditation goes digital in new clinical trial
    Scientists at UC San Francisco have developed a personalized digital meditation training program that significantly improved attention and memory in healthy young adults -- a group already at the peak of brain health -- in just six weeks.

    Could blockchain ensure integrity of clinical trial data?
    UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain.

    Eating crickets can be good for your gut, according to new clinical trial
    A new clinical trial shows that consuming crickets can help support the growth of beneficial gut bacteria and that eating crickets is not only safe at high doses but may also reduce inflammation in the body.

    Idera Pharmaceuticals presents clinical data from the ILLUMINATE-204 trial of the combination of tilsotolimod and ipilimumab for anti-PD-1 refractory metastatic melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting
    Idera Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with rare cancers and rare diseases, announced results from the ongoing ILLUMINATE-204 trial investigating tilsotolimod, Idera's intratumorally-delivered Toll-like Receptor 9 agonist, in combination with ipilimumab (Yervoy®).

    Read More: Clinical Trial News and Clinical Trial Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.